HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion.

AbstractBACKGROUND:
Regulatory B (Breg) cells represent one of the B cell subsets that infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the phenotype, function and clinical relevance of Breg cells in human hepatocellular carcinoma (HCC) are presently unknown.
METHODS:
Flow cytometry analyses were performed to determine the levels, phenotypes and functions of TIM-1+Breg cells in samples from 51 patients with HCC. Kaplan-Meier plots for overall survival and disease-free survival were generated using the log-rank test. TIM-1+Breg cells and CD8+ T cells were isolated, stimulated and/or cultured in vitro for functional assays. Exosomes and B cells were isolated and cultured in vitro for TIM-1+Breg cell expansion assays.
RESULTS:
Patients with HCC showed a significantly higher TIM-1+Breg cell infiltration in their tumor tissue compared with the paired peritumoral tissue. The infiltrating TIM-1+Breg cells showed a CD5highCD24-CD27-/+CD38+/high phenotype, expressed high levels of the immunosuppressive cytokine IL-10 and exhibited strong suppressive activity against CD8+ T cells. B cells activated by tumor-derived exosomes strongly expressed TIM-1 protein and were equipped with suppressive activity against CD8+ T cells similar to TIM-1+Breg cells isolated from HCC tumor tissue. Moreover, the accumulation of TIM-1+Breg cells in tumors was associated with advanced disease stage, predicted early recurrence in HCC and reduced HCC patient survival. Exosome-derived HMGB1 activated B cells and promoted TIM-1+Breg cell expansion via the Toll like receptor (TLR) 2/4 and mitogen-activated protein kinase (MAPK) signaling pathways.
CONCLUSIONS:
Our results illuminate a novel mechanism of TIM-1+Breg cell-mediated immune escape in HCC and provide functional evidence for the use of these novel exosomal HMGB1-TLR2/4-MAPK pathways to prevent and to treat this immune tolerance feature of HCC.
AuthorsLinsen Ye, Qi Zhang, Yusheng Cheng, Xiaolong Chen, Guoying Wang, Mengchen Shi, Tong Zhang, Yingjiao Cao, Hang Pan, Liting Zhang, Genshu Wang, Yinan Deng, Yang Yang, Guihua Chen
JournalJournal for immunotherapy of cancer (J Immunother Cancer) Vol. 6 Issue 1 Pg. 145 (12 10 2018) ISSN: 2051-1426 [Electronic] England
PMID30526680 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Cytokines
  • HAVCR1 protein, human
  • HMGB1 Protein
  • Hepatitis A Virus Cellular Receptor 1
  • Toll-Like Receptors
  • Mitogen-Activated Protein Kinases
Topics
  • B-Lymphocytes, Regulatory (immunology, metabolism)
  • Biomarkers
  • Carcinoma, Hepatocellular (etiology, metabolism, mortality, pathology)
  • Cytokines (metabolism)
  • Exosomes (metabolism)
  • Fluorescent Antibody Technique
  • HMGB1 Protein (metabolism)
  • Hepatitis A Virus Cellular Receptor 1
  • Humans
  • Immunohistochemistry
  • Immunomodulation
  • Immunophenotyping
  • Liver Neoplasms (etiology, metabolism, mortality, pathology)
  • Lymphocyte Activation (immunology)
  • Lymphocytes, Tumor-Infiltrating (immunology, metabolism)
  • Mitogen-Activated Protein Kinases (metabolism)
  • Signal Transduction
  • Toll-Like Receptors (metabolism)
  • Tumor Escape
  • Tumor Microenvironment (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: